Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?

Opportunistic Infections Project Team of the Collaboration of Ob, ; Mocroft, Amanda; Reiss, Peter; Kirk, Ole; Mussini, Cristina; Girardi, Enrico; Morlat, Philippe; Stephan, Christoph; De Wit, Stephane; Doerholt, Katja; Ghosn, Jade; Bucher, Heiner C; Lundgren, Jens D; Chene, Genevieve; Miro, Jose M; Furrer, Hansjakob (2010). Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL? Clinical infectious diseases, 51(5), pp. 611-9. Cary, N.C.: Oxford University Press 10.1086/655761

Full text not available from this repository. (Request a copy)

Current guidelines suggest that primary prophylaxis for Pneumocystis jiroveci pneumonia (PcP) can be safely stopped in human immunodeficiency virus (HIV)-infected patients who are receiving combined antiretroviral therapy (cART) and who have a CD4 cell count >200 cells/microL. There are few data regarding the incidence of PcP or safety of stopping prophylaxis in virologically suppressed patients with CD4 cell counts of 101-200 cells/microL.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

UniBE Contributor:

Furrer, Hansjakob

ISSN:

1058-4838

Publisher:

Oxford University Press

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:12

Last Modified:

06 Dec 2013 13:22

Publisher DOI:

10.1086/655761

PubMed ID:

20645862

Web of Science ID:

000280623900021

URI:

https://boris.unibe.ch/id/eprint/2702 (FactScience: 205569)

Actions (login required)

Edit item Edit item
Provide Feedback